Mallinckrodt plc to report fourth quarter and full-year fiscal 2014
results on november 19, 2014
Dublin--(business wire)--mallinckrodt plc (nyse: mnk) will report fourth quarter and full-year fiscal 2014 results on november 19, 2014. the company will hold a conference call for investors beginning at 8:30 a.m. u.s. eastern time. the call can be accessed in three ways: at the mallinckrodt website: http://www.mallinckrodt.com/investor_relations/. by telephone: for both “listen-only” participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the u.s. is (877) 359-9508. for participants outside the u.s., the dial-in number is (224) 357-2393. all callers will be required to provide the conference id of 19935233. through an audio replay: a replay of the call will be available beginning wednesday afternoon, november 19, 2014, and ending at 11:59 p.m. u.s. eastern time on november 26, 2014. the dial-in numbers for u.s. participants are (855) 859-2056 or (800) 585-8367. for participants outside the u.s., the replay dial-in number is (404) 537-3406. all callers will be required to provide the conference id of 19935233. about mallinckrodt: mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the global medical imaging segment include contrast media and nuclear imaging agents. mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. the company's fiscal 2013 revenue totaled $2.2 billion. to learn more about mallinckrodt, visit www.mallinckrodt.com.
MNK Ratings Summary
MNK Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission